Which medications in the drug class Antidysrhythmics, II are used in the treatment of Wellens Syndrome?

Updated: Jan 25, 2018
  • Author: Benjamin B Mattingly, MD; Chief Editor: Erik D Schraga, MD  more...
  • Print

Antidysrhythmics, II

Antiarrhythmic agents reduce episodes of chest pain and clinical cardiac events.

Esmolol (Brevibloc)

Esmolol is an ultra–short-acting agent that selectively blocks beta1-receptors with little or no effect on beta2-receptor types. It is particularly useful in patients with elevated arterial pressure, especially if surgery is planned. Esmolol has been shown to reduce episodes of chest pain and clinical cardiac events in comparison with placebo. It can be discontinued abruptly if necessary.

Esmolol is useful in patients at risk for complications from beta blockade, particularly those with reactive airway disease, mild-to-moderate left ventricular dysfunction, or peripheral vascular disease. Its short half-life (8 min) allows titration to the desired effect and quick discontinuance if necessary.

Propranolol (Inderal LA, InnoPran XL)

Propranolol has membrane-stabilizing activity and decreases the automaticity of contractions. It is not suitable for emergency treatment of hypertension. Do not administer it intravenously in hypertensive emergencies.

Sotalol (Betapace, Sorine)

This class II antiarrhythmic agent blocks K+ channels, increases sinus cycle length, slows the heart rate, increases AV nodal refractoriness, and decreases AV nodal conduction. It has been shown to be effective in the maintenance of sinus rhythm, even in patients with underlying structural heart disease. It is a non–cardiac selective beta-adrenergic blocker. It has both beta1 and beta2 receptor blocking activity.

Acebutolol (Sectral)

Acebutolol selectively blocks beta1-adrenergic receptors. It has intrinsic activity and membrane stabilizing activity.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!